 |
|
|
| |
Integrated Efficacy and Safety Analysis of Genotypes 1-6 Treatment-Naïve, Non-Cirrhotic, and Compensated Cirrhotic Hispanic/Latino Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir
|
| |
| |
AASLD 2020 virtual Nov 11-15
Reported by Jules Levin
Julio A Gutierrez1, Eli Zuckerman2, Douglas E Dylla3, Victor de Ledinghen4, Andrew J Muir5, Michael Gschwantler6, Massimo Puoti7, Jihad Slim8, Frederik Nevens9, Linda M Fredrick3, Nancy Agront3, Margaret Burroughs31Scripps Clinic, Center for Organ and Cell Transplantation, La Jolla, California, United States; 2Liver Unit, Carmel Medical Center, Faculty of Medicine, Technion Institute, Haifa, Israel; 3AbbVie Inc., North Chicago, Illinois, United States; 4Centre d'Investigation de la Fibrose Hépatique, Bordeaux University Hospital, Pessac, France; INSERM U1053, Bordeaux University, Bordeaux, France; 5Duke Clinical Research Institute, Durham, North Carolina, United States; 6Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria; Sigmund Freud University, Vienna, Austria; 7Niguarda ca Grande Hospital, Milan, Italy; 8Infectious Disease Division, Department of Internal Medicine, St. Michael's Medical Center, Newark, New Jersey, United States; 9Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Belgium
|
| |
|
|
|
|
|
